0.65
price up icon2.75%   0.0174
after-market After Hours: .63 -0.02 -3.08%
loading
Indaptus Therapeutics Inc stock is traded at $0.65, with a volume of 121.10K. It is up +2.75% in the last 24 hours and down -17.27% over the past month.
See More
Previous Close:
$0.6326
Open:
$0.62
24h Volume:
121.10K
Relative Volume:
0.32
Market Cap:
$9.38M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-0.3533
EPS:
-1.84
Net Cash Flow:
$-13.41M
1W Performance:
-13.93%
1M Performance:
-17.27%
6M Performance:
-50.00%
1Y Performance:
-73.90%
1-Day Range:
Value
$0.62
$0.674
1-Week Range:
Value
$0.58
$0.78
52-Week Range:
Value
$0.58
$3.10

Indaptus Therapeutics Inc Stock (INDP) Company Profile

Name
Name
Indaptus Therapeutics Inc
Name
Phone
(646) 427-2727
Name
Address
3 COLUMBUS CIRCLE, NEW YORK
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-08-12
Name
Latest SEC Filings
Name
INDP's Discussions on Twitter

Compare INDP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
INDP
Indaptus Therapeutics Inc
0.65 9.38M 0 -15.42M -13.41M -1.84
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.55 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
635.83 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
593.47 36.20B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
271.02 35.08B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
262.60 28.24B 3.81B -644.79M -669.77M -6.24

Indaptus Therapeutics Inc Stock (INDP) Latest News

pulisher
Mar 26, 2025

Indaptus Therapeutics Inc (NASDAQ: INDP) Stock Is Down -10.94% From Its Low: The Uptrend Is Still On - Stocks Register

Mar 26, 2025
pulisher
Mar 25, 2025

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Top Biotech CMO Summit Taps Indaptus Expert to Guide Clinical Trial Excellence Discussion - StockTitan

Mar 25, 2025
pulisher
Mar 22, 2025

Selling Your Indaptus Therapeutics Inc (NASDAQ: INDP) Stock? Here’s What You Need To Know - Stocks Register

Mar 22, 2025
pulisher
Mar 21, 2025

Indaptus Therapeutics looks to raise $2.25M in private placement - MSN

Mar 21, 2025
pulisher
Mar 20, 2025

Indaptus reports progress in Decoy20 cancer therapy trial By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

INDP stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

INDP stock touches 52-week low at $0.7 amid market challenges - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Indaptus Therapeutics Says New Data on Decoy20 Shows Broad Immune System Activation in Cancer Patients - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Indaptus reports progress in Decoy20 cancer therapy trial - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Breakthrough: Indaptus Cancer Drug Successfully Activates Immune System in Weekly Dosing Trial - StockTitan

Mar 20, 2025
pulisher
Mar 19, 2025

Indaptus tests new cancer therapy combination By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Indaptus tests new cancer therapy combination - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Groundbreaking Cancer Trial: Indaptus Combines Novel Decoy20 with Checkpoint Inhibitor - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors - Benzinga India

Mar 18, 2025
pulisher
Mar 18, 2025

Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Drop in Short Interest - Defense World

Mar 18, 2025
pulisher
Mar 13, 2025

INDAPTUS THERAPEUTICS Earnings Results: $INDP Reports Quarterly Earnings - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Indaptus Therapeutics reports full-year loss of $1.61 per share -March 13, 2025 at 07:40 am EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Indaptus Therapeutics Enrolls Over 20 Patients in Phase 1 Trial of Decoy20, Achieving Key Clinical Milestone - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Indaptus Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 12, 2025

Registration Is Now Open For Tribe Public’s Webinar Event - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

Registration Is Now Open For Tribe Public's Webinar Event 'Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025 - The Manila Times

Mar 12, 2025
pulisher
Mar 12, 2025

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

Registration Is Now Open For Tribe Public’s Webinar Event "Keys To The Kingdom: Unlocking The Power Of Your Immune System" Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Revolutionary Immune System Technology Unveiled: Indaptus CEO to Share Groundbreaking Insights - StockTitan

Mar 12, 2025
pulisher
Mar 07, 2025

Indaptus Therapeutics extends patent portfolio in China, Japan, and Israel - BSA bureau

Mar 07, 2025
pulisher
Mar 05, 2025

Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Wednesday - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Indaptus Therapeutics Expands Patent Portfolio In China, Japan, And Israel, Strengthening Its Intellectual Property For Infectious Disease And Cancer Treatments - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Indaptus secures new patents in Asia and Israel for Decoy platform By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

Indaptus secures new patents in Asia and Israel for Decoy platform - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Indaptus Therapeutics Secures New Patent Approvals in China, Japan, and Israel for Decoy Platform in HIV and HBV Treatment - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

Can Indaptus' New Asian Patents Transform Its Position in the $4B Hepatitis B Market? - StockTitan

Mar 04, 2025
pulisher
Feb 25, 2025

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Indaptus Therapeutics (NASDAQ:INDP) Trading Down 0.6% – Should You Sell? - Defense World

Feb 25, 2025
pulisher
Feb 14, 2025

Indaptus Therapeutics Enters Standby Equity Purchase Deal With YA II PN -February 12, 2025 at 12:30 pm EST - Marketscreener.com

Feb 14, 2025
pulisher
Feb 12, 2025

Indaptus Therapeutics Enters Equity Purchase Agreement With Ya II Pn -February 12, 2025 at 09:29 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 06, 2025

Indaptus Therapeutics expands cancer trial to Canada - Investing.com India

Feb 06, 2025
pulisher
Feb 05, 2025

Indaptus Therapeutics Files Prospectus Relating To Proposed Resale By Selling Stockholders Of Up To 4.4 Million Shares - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Indaptus Therapeutics Expands Decoy20 Clinical Trial To Canada - Nasdaq

Feb 05, 2025
pulisher
Feb 05, 2025

Indaptus Therapeutics expands cancer trial to Canada By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 - The Manila Times

Feb 05, 2025
pulisher
Feb 05, 2025

Major Clinical Trial Expansion: Indaptus' Cancer Immunotherapy Decoy20 Gets Canadian Green Light - StockTitan

Feb 05, 2025
pulisher
Feb 03, 2025

Head-To-Head Contrast: Indaptus Therapeutics (NASDAQ:INDP) vs. Biofrontera (NASDAQ:BFRI) - Defense World

Feb 03, 2025
pulisher
Feb 01, 2025

Indaptus Therapeutics Receives Notification from Nasdaq Regarding Minimum Bid Price RequirementUnited States Securities and Exchange Commission, Washington, DC 20549Form 8-KIndaptus Therapeutics, Inc. recently received a notification from Nasda - Defense World

Feb 01, 2025
pulisher
Jan 15, 2025

Indaptus Therapeutics Announces $2.25 Million Private Placement - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

Indaptus Therapeutics, Inc. announced that it expects to receive $2.246493 million in funding - Marketscreener.com

Jan 14, 2025

Indaptus Therapeutics Inc Stock (INDP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.69
price up icon 1.46%
$308.02
price down icon 0.90%
$31.65
price up icon 0.29%
$20.60
price up icon 3.57%
$95.40
price down icon 0.52%
biotechnology ONC
$262.60
price up icon 4.65%
Cap:     |  Volume (24h):